Concepedia

Ann Cleverly

AC

Statistics

Publications

36

Citations

2.6K

H-Index

25

Active since

1991

Affiliations

Eli Lilly (United States)(Current)

Eli Lilly (United Kingdom)

Vall d'Hebron Hospital Universitari

Hospital Universitario 12 De Octubre

Universitat Autònoma de Barcelona

Ann Cleverly is an author at Eli Lilly (United States) specializing in medicine, pharmacology, and oncology.

Publications per year

1991–2021

36

Publications

36

Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer

Davide Melisi, Rocio García‐Carbonero, Teresa Macarulla et al. · British Journal of Cancer · 2018 · 274 citations · Full text

, , +13

A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma

Alba A. Brandes, Santosh Kesari, Juan Manuel Sepúlveda-Sánchez et al. · Neuro-Oncology · 2016 · 271 citations · Full text

, , +17

A Phase 2 Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma

Robin Kate Kelley, Edward Gane, Eric Assénat et al. · Clinical and Translational Gastroenterology · 2019 · 245 citations · Full text

, , +17

First-in-Human Dose Study of the Novel Transforming Growth Factor-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Patients with Advanced Cancer and Glioma

Jordi Rodón, Michael A. Carducci, Juan Manuel Sepúlveda-Sánchez et al. · Clinical Cancer Research · 2014 · 232 citations

, , +13

Novel transforming growth factor beta receptor I kinase inhibitor galunisertib (LY2157299) in advanced hepatocellular carcinoma

Sandrine Faivre, Armando Santoro, Robin Kate Kelley et al. · Liver International · 2019 · 143 citations

, , +17

1–5 of 36